Guardant Health, Inc.

NasdaqGS GH

Guardant Health, Inc. Gross Profit Margin for the Trailing 12 Months (TTM) ending September 30, 2024: 81.07%

Guardant Health, Inc. Gross Profit Margin is 81.07% for the Trailing 12 Months (TTM) ending September 30, 2024, a 34.00% change year over year. Gross Profit Ratio is the ratio of gross profit to net sales, indicating the percentage of revenue that exceeds the cost of goods sold and reflects the efficiency of a company in managing its production or procurement and sales.

Guardant Health, Inc. Gross Profit Margin for the Trailing 12 Months (TTM) ending September 30, 2023 was 60.50%, a -9.56% change year over year.
Guardant Health, Inc. Gross Profit Margin for the Trailing 12 Months (TTM) ending September 30, 2022 was 66.89%, a 1.79% change year over year.
Guardant Health, Inc. Gross Profit Margin for the Trailing 12 Months (TTM) ending September 30, 2021 was 65.71%, a -3.81% change year over year.
Guardant Health, Inc. Gross Profit Margin for the Trailing 12 Months (TTM) ending September 30, 2020 was 68.31%, a 3.63% change year over year.

Key data

Date	Gross Profit Margin	Operating Income Margin	EBT Margin	Net Income Margin

NasdaqGS: GH

Guardant Health, Inc.

CEO	Dr. Helmy Eltoukhy Ph.D.
IPO Date	Oct. 4, 2018
Location	United States
Headquarters	505 Penobscot Drive
Employees	1,768
Sector	Health Care
Industries Pharmaceuticals Clinical Trials

Description

Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 LDT, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a clinical-genomic liquid biopsy dataset of advanced cancer patients. It is also developing LUNAR-2 test for the early detection of colorectal cancer in asymptomatic individuals eligible; and GuardantConnect, an integrated software-based solution for clinical and biopharmaceutical customers seeking to connect patients tested with the Guardant360 assay with actionable alterations with potentially relevant clinical trials. In addition, the company offers Guardant Reveal Test for neoadjuvant and adjuvant treatment selection in early-stage cancer patients; Guardant360 tissue genotyping product; and Guardant-19 for use in the detection of the novel coronavirus. Further, it offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, and kits fulfillment related services to biopharmaceutical companies and medical institutions. The company was incorporated in 2011 and is headquartered in Redwood City, California.

Key trends

Past 5 years